Psychotropic drug–related weight gain (PDWG) is a common occurrence and is highly
associated with non-initiation, discontinuation, and dissatisfaction with psychiatric drugs …

The long-term use of antipsychotics (APs) may cause a variety of diseases, such as
metabolic syndrome, antipsychotic-induced weight gain (AIWG), and even obesity. This …

There is an urgent need for mechanistically novel and more efficacious treatments for
schizophrenia, especially those targeting negative and cognitive symptoms with a more …

Purpose This systematic review was conducted to determine which type of oral medication
for obesity provides the best weight loss effect. Methods This study adhered to the Preferred …

O presente relatório diz respeito ao estágio curricular realizado para obtenção do grau de
Mestre, última etapa do Mestrado Integrado em Ciências Farmacêuticas. Descreve aquilo …

Background: Antipsychotic use increases the risk of weight gain and metabolic
complications. We aimed to investigate the effect of topiramate on weight loss and metabolic …

Antipsychotika (früherer Begriff Neuroleptika) sind Neuro‑/Psychopharmaka, die vorrangig
zur symptomatischen Behandlung von Erkrankungen aus dem schizophrenen Formenkreis …